Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1 drug Opdivo (nivolumab) across various cancer indications. Early results from a Phase III trial in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) indicate that the combination of Opdivo with anti-CTLA-4 Yervoy (ipilimumab) reduced the risk of disease progression or death by 79% compared to Opdivo alone or chemotherapy.
In the realm of first-line advanced or metastatic renal cell carcinoma (RCC), a 4-year follow-up of patients receiving Opdivo in combination with Exelixis’s (NASDAQ: EXEL) multikinase inhibitor Cabometyx (cabozantinib) showed a nearly doubled progression-free survival (PFS), extending from 8.4 months with sunitinib, originally developed by Pfizer (NYSE: PFE) under the brand Sutent, to 16.4 months. This regimen also demonstrated a significant increase in overall survival (OS), stretching from 36.0 months to 46.5 months.
In a separate long-term study for the same RCC indication, the combination of Opdivo and Yervoy was found to increase the 8-year median OS to 46.7 months from 26.0 months with sunitinib, representing a 31% reduction in the risk of death.- Flcube.com
